dr reddy’s

Dr. Reddy’s Laboratories shares gained on Monday in the backdrop of the drugmaker announcing successful completion of a phase-1 study of its proposed biosimilar of tocilizumab for use in the…

A bottle of Revlimid and pills are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S. File | Photo Credit: Reuters Dr. Reddy’s Laboratories and a…

“There is no denying the fact that all of these listed digital companies are outstanding businesses and if you want to make money in equities, the thumb rule is to buy an outstanding…

ICICI Bank among 6 top investment ideas for this month - Top Picks | The Economic Times05 Nov 2022, 10:59 AM ISTIn the month of October, while Nifty clocked over 5% gains, it underperformed…

Stocks to Watch Today: The key benchmark…

For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to the prior year For the full year…

Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain rights to New Jersey-based Slayback Pharma’s Brimonidine Tartrate Ophthalmic Solution 0.025%.Slayback…

Equity benchmark Sensex fell over 277 points in opening trade on Thursday, June 9, 2022,tracking losses in index majors Asian Paints, TCS and HCL Tech amid a negative trend in global…

Move expected to help Dr. Reddy’s sharpen focus on key therapy spaces  Move expected to help Dr. Reddy’s sharpen focus on key therapy spaces  Russian drugmaker Binnopharm Group is in the…

Pharma major Dr. Reddy’s Laboratories reported consolidated net profit surged to ₹709.3 crore in the December quarter on improved sales in mainstay generics and a sharp decline in…